Compare CSTL & GSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTL | GSM |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Metal Mining |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 940.8M | 964.9M |
| IPO Year | 2019 | 2015 |
| Metric | CSTL | GSM |
|---|---|---|
| Price | $29.72 | $5.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $46.67 | $6.00 |
| AVG Volume (30 Days) | 390.1K | ★ 1.3M |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 1.15% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $344,229,000.00 | N/A |
| Revenue This Year | $3.15 | $20.44 |
| Revenue Next Year | N/A | $15.86 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.66 | N/A |
| 52 Week Low | $14.59 | $2.97 |
| 52 Week High | $44.28 | $5.74 |
| Indicator | CSTL | GSM |
|---|---|---|
| Relative Strength Index (RSI) | 33.66 | 52.10 |
| Support Level | $21.77 | $4.71 |
| Resistance Level | $34.97 | $5.52 |
| Average True Range (ATR) | 1.71 | 0.35 |
| MACD | -0.10 | -0.00 |
| Stochastic Oscillator | 31.72 | 37.64 |
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
Ferroglobe PLC provides silicon-based alloys and specialty metals. It produces silicon metal and silicon and manganese-based alloy, serving customers in the specialty chemical, aluminum, solar, steel, and ductile iron foundry industries. The company's business segments include North America- Silicon, North America -Silicon Alloys; Europe Manganese; Europe Silicon Metals; Europe -Silicon Alloys, South Africa Silicon Metals, South Africa-Silicon Alloys, and Other segments The primary raw materials company uses to produce its electrometallurgy products includes its coal and quartz mining operations and its silicon metal and ferroalloy production.